Non-invasive urine testing of EGFR activating mutation and T790M resistance mutation in non-small cell lung cancer

被引：18
作者：
Berz D. [1 ]
Raymond V.M. [2 ]
Garst J.H. [2 ]
Erlander M.G. [2 ]
机构：
[1] Beverly Hills Cancer Center, 8900 Wilshire Boulevard, Beverly Hills, 90211, CA
[2] Trovagene, Inc, 11055 Flintkote Avenue, San Diego, 92121, CA
来源：
Experimental Hematology & Oncology | / 5卷 / 1期
关键词：
Cell free DNA; Circulating tumor DNA; CtDNA; Diagnostics; EGFR; Liquid biopsy; Lung cancer; Targeted therapy; Urine;
D O I：
10.1186/s40164-016-0052-3
中图分类号：
学科分类号：
摘要：
Background: The increasing understanding of non-small cell lung cancer (NSCLC) biology over the last two decades has led to the identification of multiple molecular targets. This led to the development of multiple targeted therapies in the primary and secondary resistance setting and the epidermal growth factor receptor (EGFR) gene remains the most frequently observed molecular target in NSCLC. Tissue biopsies remain the standard for the identification of such EGFR mutations. Obtaining serial tissue biopsies, especially in the secondary resistance setting is associated with multiple medical and logistical challenges. Utilizing circulating tumor DNA (ctDNA) fragments for molecular analysis can overcome these challenges and aid in therapeutic decision-making. Case presentation: Here we present a present a 72-year-old Korean woman with metastatic, EGFR L858R mutated bronchogenic adenocarcinoma. She developed skeletal progression on treatment with first and second generation tyrosine kinase inhibitors (TKIs). Repeated biopsies failed to provide informative molecular test results. A novel urine ctDNA assay was utilized and confirmed T790M positive status. The patient was started on a third generation TKI, which led to a measurable clinical response. Conclusions: Utilization of urine liquid biopsies for EGFR diagnostics are feasible and provided critical clinical information in this patient's case. Urine liquid biopsy represents a viable alternative to tissue biopsy, particularly in the secondary resistance setting, when tissue is not available for molecular testing. © 2016 The Author(s).
引用
收藏
相关论文
共 35 条
[1]  
Imielinski M., Berger A.H., Hammerman P.S., Et al., Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing, Cell, 150, 6, pp. 1107-1120, (2012)
[2]  
Rosell R., Moran T., Queralt C., Et al., Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, 361, 10, pp. 958-967, (2009)
[3]  
Collisson E.A., Campbell J.D., Brooks A.N., Et al., Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 7511, pp. 543-550, (2014)
[4]  
Shi Y., Au J.-K., Thongprasert S., Et al., A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER), J Thorac Oncol, 9, 2, pp. 154-162, (2014)
[5]  
Russo A., Franchina T., Ricciardi G.R.R., Et al., A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): old successes and future perspectives, Oncotarget, 6, 29, pp. 26814-26825, (2015)
[6]  
Maemondo M., Inoue A., Kobayashi K., Et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 25, pp. 2380-2388, (2010)
[7]  
Rosell R., Carcereny E., Gervais R., Et al., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet Oncol, 13, 3, pp. 239-246, (2012)
[8]  
Sequist L.V., Yang J.-H., Yamamoto N., Et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations, J Clin Oncol, 31, 27, pp. 3327-3334, (2013)
[9]  
Wu Y.-L., Zhou C., Hu C.-P., Et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial, Lancet Oncol, 15, 2, pp. 213-222, (2014)
[10]  
Camidge D.R., Pao W., Sequist L.V., Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, 11, 8, pp. 473-481, (2014)
1234